Inhibition of Breast Cancer Metastasis by Resveratrol-mediated Inactivation of Tumor-evoked Regulatory B Cells

Overview

Journal J Immunol

Specialty Allergy & Immunology

Date 2013 Sep 18

PMID 24043896

Citations 83

Authors

Catalina Lee-Chang

Monica Bodogai

Alejandro Martin-Montalvo

Katarzyna Wejksza

Mitesh Sanghvi

Ruin Moaddel

Rafael de Cabo

Arya Biragyn

Affiliations

Soon will be listed here.

Abstract

We reported previously that tumor-evoked regulatory B cells (tBregs) play an essential role in breast cancer lung metastasis by inducing TGF-β-dependent conversion of metastasis-promoting Foxp3(+) regulatory T cells (Tregs). In this article, we show that resveratrol (RSV), a plant-derived polyphenol, at low and noncytotoxic doses for immune cells, can efficiently inhibit lung metastasis in mice. The mechanism of this process is that RSV inactivates Stat3, preventing the generation and function of tBregs, including expression of TGF-β. As a result, it frees antitumor effector immune responses by disabling tBreg-induced conversion of Foxp3(+) Tregs. We propose that low doses of RSV may also benefit humans by controlling cancer escape-promoting tBregs/Tregs without nonspecific inactivation of effector immune cells.

Citing Articles

Tumor-infiltrating and circulating B cells mediate local and systemic immunomodulatory mechanisms in Glioblastoma.

De Domenico P, Gagliardi F, Roncelli F, Snider S, Mortini P J Neurooncol. 2025; .

PMID: 40080248 DOI: 10.1007/s11060-025-04989-z.

Natural products: promising therapeutics for targeting regulatory immune cells in the tumor microenvironment.

Song P, Song F, Shao T, Wang P, Li R, Chen Z Front Pharmacol. 2024; 15:1481850.

PMID: 39605905 PMC: 11598344. DOI: 10.3389/fphar.2024.1481850.

Endothelial cells in tumor microenvironment: insights and perspectives.

Leone P, Malerba E, Susca N, Favoino E, Perosa F, Brunori G Front Immunol. 2024; 15:1367875.

PMID: 38426109 PMC: 10902062. DOI: 10.3389/fimmu.2024.1367875.

The Combination of Bioavailable Concentrations of Curcumin and Resveratrol Shapes Immune Responses While Retaining the Ability to Reduce Cancer Cell Survival.

Focaccetti C, Palumbo C, Benvenuto M, Carrano R, Melaiu O, Nardozi D Int J Mol Sci. 2024; 25(1).

PMID: 38203402 PMC: 10779126. DOI: 10.3390/ijms25010232.

Exploring the dual role of B cells in solid tumors: implications for head and neck squamous cell carcinoma.

Bao J, Betzler A, Hess J, Brunner C Front Immunol. 2023; 14:1233085.

PMID: 37868967 PMC: 10586314. DOI: 10.3389/fimmu.2023.1233085.

References

Olkhanud P, Rochman Y, Bodogai M, Malchinkhuu E, Wejksza K, Xu M . Thymic stromal lymphopoietin is a key mediator of breast cancer progression. J Immunol. 2011; 186(10):5656-62. PMC: 3401482. DOI: 10.4049/jimmunol.1100463. View

Kotha A, Sekharam M, Cilenti L, Siddiquee K, Khaled A, Zervos A . Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther. 2006; 5(3):621-9. DOI: 10.1158/1535-7163.MCT-05-0268. View

Bunt S, Sinha P, Clements V, Leips J, Ostrand-Rosenberg S . Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol. 2005; 176(1):284-90. DOI: 10.4049/jimmunol.176.1.284. View

Nagaraj S, Gabrilovich D . Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res. 2008; 68(8):2561-3. DOI: 10.1158/0008-5472.CAN-07-6229. View

Klink J, Tewari A, Masko E, Antonelli J, Febbo P, Cohen P . Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways. Prostate. 2012; 73(7):754-62. PMC: 3628095. DOI: 10.1002/pros.22619. View

Olkhanud P, Damdinsuren B, Bodogai M, Gress R, Sen R, Wejksza K . Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells. Cancer Res. 2011; 71(10):3505-15. PMC: 3096701. DOI: 10.1158/0008-5472.CAN-10-4316. View

Wejksza K, Lee-Chang C, Bodogai M, Bonzo J, Gonzalez F, Lehrmann E . Cancer-produced metabolites of 5-lipoxygenase induce tumor-evoked regulatory B cells via peroxisome proliferator-activated receptor α. J Immunol. 2013; 190(6):2575-84. PMC: 3594535. DOI: 10.4049/jimmunol.1201920. View

Jang M, Cai L, Udeani G, Slowing K, Thomas C, Beecher C . Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997; 275(5297):218-20. DOI: 10.1126/science.275.5297.218. View

Pandey P, Xing F, Sharma S, Watabe M, Pai S, Iiizumi-Gairani M . Elevated lipogenesis in epithelial stem-like cell confers survival advantage in ductal carcinoma in situ of breast cancer. Oncogene. 2012; 32(42):5111-22. DOI: 10.1038/onc.2012.519. View

10.

Tiwari V, Chopra K . Resveratrol prevents alcohol-induced cognitive deficits and brain damage by blocking inflammatory signaling and cell death cascade in neonatal rat brain. J Neurochem. 2011; 117(4):678-90. DOI: 10.1111/j.1471-4159.2011.07236.x. View

11.

Jeong M, Yang K, Choi Y, Kim S, Yoo Y, Seo S . Resveratrol analog, HS-1793 enhance anti-tumor immunity by reducing the CD4+CD25+ regulatory T cells in FM3A tumor bearing mice. Int Immunopharmacol. 2012; 14(3):328-33. DOI: 10.1016/j.intimp.2012.07.018. View

12.

Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E . Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood. 2005; 106(6):2018-25. DOI: 10.1182/blood-2005-02-0642. View

13.

Guan H, Singh N, Singh U, Nagarkatti P, Nagarkatti M . Resveratrol prevents endothelial cells injury in high-dose interleukin-2 therapy against melanoma. PLoS One. 2012; 7(4):e35650. PMC: 3331985. DOI: 10.1371/journal.pone.0035650. View

14.

de Visser K, Korets L, Coussens L . De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell. 2005; 7(5):411-23. DOI: 10.1016/j.ccr.2005.04.014. View

15.

Serafini P, De Santo C, Marigo I, Cingarlini S, Dolcetti L, Gallina G . Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother. 2003; 53(2):64-72. PMC: 11032848. DOI: 10.1007/s00262-003-0443-2. View

16.

Qin Z, Richter G, Schuler T, Ibe S, Cao X, Blankenstein T . B cells inhibit induction of T cell-dependent tumor immunity. Nat Med. 1998; 4(5):627-30. DOI: 10.1038/nm0598-627. View

17.

Woo E, Yeh H, Chu C, Schlienger K, Carroll R, Riley J . Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 2002; 168(9):4272-6. DOI: 10.4049/jimmunol.168.9.4272. View

18.

Youn J, Nagaraj S, Collazo M, Gabrilovich D . Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol. 2008; 181(8):5791-802. PMC: 2575748. DOI: 10.4049/jimmunol.181.8.5791. View

19.

Pan P, Ma G, Weber K, Ozao-Choy J, Wang G, Yin B . Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res. 2009; 70(1):99-108. PMC: 2805053. DOI: 10.1158/0008-5472.CAN-09-1882. View

20.

Lelekakis M, Moseley J, Martin T, Hards D, Williams E, Ho P . A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis. 1999; 17(2):163-70. DOI: 10.1023/a:1006689719505. View